Citations

Clear

2416 citation(s) found for "Yu, Jason".

Mutational burden on circulating cell-free tumor-DNA testing as a surrogate marker of mismatch repair deficiency/microsatellite instability and/or response to immunotherapy in patients with colorectal cancer.
Kamatham, Saivaishnavi , Merchea, Amit , Starr, Jason S. , Mody, Kabir , Colibaseanu, Dorin , Shahjehan, Faisal , Kasi, Pashtoon Murtaza

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: e15066-e15066

10.1200/jco.2019.37.15_suppl.e15066 Get It

e15066 Background: Circulating cell-free tumor-DNA (ctDNA) testing (‘liquid biopsy’) is increasingly being employed both in clinical trials as well as clinical practice. We aimed to contrast and compare the differences in the number of somatic mutations observed on ctDNA testing between mismatch repair deficient/microsatellite instability-high (dMMR/MSI-High) versus mismatch repair proficient/microsatellite stable (pMMR/MSS) colorectal cancers (CRC). Methods: We had 20 patients at Mayo Clinic Florida that were dMMR/MSI-High with testing through the commercially available platform (Guardant360) that uses a 73-gene panel. Median numbers of somatic mutations were compared between the 2 subset of CRC. Results: Patients with dMMR/MSI-High CRC had a median of 8 mutations (range: 2-15) versus a median of 4 mutations (range: 1-22) in pMMR/MSS patients, p-value of 0.001. Similarly, the mean number of somatic mutations were 7.47 (S.D. ± 4.15) versus 5.02 mutations (S.D. ± 3.83) in patients with dMMR/MSI-H and pMMR/MSS, tumors respectively. Though it is simplistic, we could still potentially identify patients who may be candidates for immunotherapy by gauging the mutational burden reported (Table). Furthermore, on serial testing, decline in mutational burden as early as few weeks into therapy was predictive of response later on imaging. Conclusions: Analysis of number of somatic mutations on ctDNA testing can be complementary to MMR/MSI-testing, especially in situations when tissue is not available or safe to obtain. This can also be of value in predicting and/or following response to immunotherapy. The utility of this may go beyond CRC in identifying patients who may benefit from immunotherapy. [Table: see text]
Circulating tumor DNA dynamics, serial testing and evolution on treatment in 322 colorectal cancer patients.
Kamatham, Saivaishnavi , Merchea, Amit , Starr, Jason S. , Mody, Kabir , Kasi, Pashtoon Murtaza , Colibaseanu, Dorin , Shahjehan, Faisal

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 3566-3566

10.1200/jco.2019.37.15_suppl.3566 Get It

3566 Background: According to the American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) joint review on circulating tumor DNA (ctDNA) issued in March 2018, widespread use of ctDNA assays in most patients with advanced cancer is still an area of ongoing research. However, multiple studies thereafter published and/or presented support its use in patients with metastatic colorectal cancer (CRC). This has led to several institutions adopting it as ‘clinical practice’. The aim of this study is to report on our institution’s adoption of ctDNA testing for every patient at the time of diagnosis and/or time of progression. Methods: We report on results of 322 CRC patients with 607 ctDNA tests at our center from January 2017 to February 2019 using a commercially available platform (Guardant360). Results: Among 322 patients of our cohort, a total of 607 ctDNA tests were done (Table). 127 (39.4%) of these tests were serial analyses. In the CRC patients who had serial testing, at progression, mechanisms of resistance included acquisition of KRAS, NRAS, EGFR mutations; and HER2- and MET-amplifications. The subclonal mutations were noted to disappear when the selective inhibition was stopped. This was seen in patients on targeted therapies/biologics rather than chemotherapy. This was of value in treatment modification, clinical trial selection and/or monitoring of disease progression in these patients. Conclusions: While ctDNA testing may not be ready for primetime in all advanced cancers, it is increasingly being adopted in practice for especially metastatic CRC. Of particular value is the serial ctDNA testing in the RAS/RAF wildtype subset and now BRAF V600E mutant CRC on anti-EGFR based therapies. [Table: see text]
Impact of a breast cancer (BC) polygenic risk score (PRS) on the decision to take preventive endocrine therapy (ET): The Genetic Risk Estimate (GENRE) trial.
Schaid, Daniel J. , Cooke, Andrew , Highsmith, W. Edward, Grenier, Debjani, Vachon, Celine M. , Pruthi, Sandhya , Kim, Julian O. , Kim, Christina , Goldenberg, Benjamin A. , Sinnwell, Jason P. , Degnim, Amy C. , Couch, Fergus J. , Vachon, Celine M.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 1501-1501

10.1200/jco.2019.37.15_suppl.1501 Get It

1501 Background: Despite BC risk reduction of 50-65% by preventive endocrine therapy (ET), very few at-risk women choose to take them. A woman’s perceived BC risk correlates with uptake of ET. A PRS comprised of 77 BC genetic susceptibility loci (Single Nucleotide Polymorphisms (SNP) improves the accuracy of risk prediction for BC. We examined the impact of the addition of individualized PRS BC risk prediction to standard risk calculator estimates on intent to take BC prevention medication. Methods: Eligible women had ≥5% 10 yr BC Tyrer-Cuzick risk (IBIS) or 5 year Gail score ≥3%, with no history of BC or hereditary BC syndrome. Standard BC risk estimates (IBIS or Gail) were incorporated into the counselling on BC preventive ET. A self-reported questionnaire at baseline quantified intention to take ET and explored factors associated with this decision. Blood samples were obtained and genotyped for 77 SNPs, individualized PRS were calculated then incorporated into IBIS and Gail predictions for 5 yr, 10 yr, & lifetime BC risk. At a second visit, PRS risk & prevention recommendations were revisited. Post visit questionnaires assessed change in intent to take ET. Multivariable linear regression was performed to assess impact of baseline variables on change in intent to take medication. Results: From 2016 to 2017, 151 women in Canada & USA were enrolled, median age: 56.1 (range 36-76.4), 35.6% were premenopausal, 98.7% were Caucasian. Median 5yr, 10yr, & lifetime IBIS risk estimates were 3.8% (2.0-11.5), 7.9% (5.0-23.1), and 25.3% (5.5 to 92.2). PRS increased BC risk estimates in 84 (55.6%) and reduced BC risk estimates in 67 (44%) women. After PRS risk counselling, intention to take ET significantly changed (p<0.001): 41.9% of those with increased PRS were more inclined, and 46.7% of women with decreased PRS were less inclined to take ET. On multivariable regression, increase in PRS (p<0.0001) and less concern about ET side effects (p<0.0001) were associated with greater intent to take ET. Conclusions: In high risk women, PRS significantly changed BC risk estimates & intent to take preventive ET. Further assessments of the impact of PRS scores on compliance with ET are warranted. Clinical trial information: NCT02517593.
Tumor subtype and other prognostic factors in breast cancer patients with brain metastases: The updated graded prognostic assessment (Breast-GPA).
Sperduto, Paul W. , Cagney, Daniel , Nesbit, Eric , Chan, Jason W., Breen, Will, Soliman, Hany , Shanley, Ryan , Everett, Ashlyn S. , Masucci, Laura , Plichta, Kristin A. , Jain, Supriya , Bryant, John , Nakano, Toshimichi , Mesko, Shane , Lee, Jessica , Shi, Diana D. , Remick, Jill S. , Wu, Cheng–Chia , Yu, James B. , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 1079-1079

10.1200/jco.2019.37.15_suppl.1079 Get It

1079 Background: Brain metastases (BM) are a common and fatal complication of breast cancer but survival varies widely based on various prognostic factors (PF). Hence, patient counseling and therapeutic decisions should be individualized. We previously published a prognostic index (Breast GPA) based on cohort A (1985-2007, n = 642), updated it with tumor subtype in cohort B (1993-2010, n = 400) and are now updating it with a larger contemporary cohort (C). Methods: A multi-institutional (19) multi-national (3) retrospective database of 2473 breast cancer patients with BM diagnosed from 1/1/2006-12/31/2017 was created and compared to our prior cohorts. Demographic, clinical, molecular factors, tumor subtype and treatment were correlated with survival. Kaplan-Meier survival estimates were calculated and compared with log-rank tests. Results: The median survival (MS) for cohorts A, B and C improved over time [12, 14 and 16 mo, respectively ( < 0.01)] despite the subtype distribution becoming less favorable: Luminal B (ER/PR/HER2+) decreased from 26% to 21%; HER2 (HER2+/ER/PR-) decreased from 31% to 17%, Luminal A (ER/PR+/HER2-) increased from 20% to 31%; Basal (ER/PR/HER2-) was unchanged at 24%.MS by subtype improved from 21 to 27 mo in Luminal B, 18 to 25 mo in HER2, 10 to 14 mo in Luminal A and 6 to 9 mo in Basal tumors. The number of BM was 1 in 35%, ≤4 in 67% and > 10 in 18%. PF significant for survival were tumor subtype, age, KPS, number of BM and extracranial metastases (ECM) (all < 0.01). Surprisingly, Hispanic women (7%) showed improved survival (p < 0.01). BRCA1 was mutated in 57/533 (11%) and those patients showed a trend (0.16) toward improved survival. Treatment patterns have changed: the use of whole brain radiation therapy decreased from 71% to 67% to 47% in cohorts A, B and C, respectively. Conclusions: Despite the shift to less favorable tumor subtypes, MS has improvedbut varies widely by diagnosis-specific PF. Compared to prior cohorts, number of BM and ECM were identified as new PF. Ethnic, genetic and treatment differences between the eras are apparent. The updated Breast GPA, based on these data, and the correlation between BRCA1 and tumor subtype will be presented.
Essential Office Procedures for Medicare Patients in Primary Care: Comparison With Family Medicine Residency Training
Poulin, Eric A., Swartz, Andrew W. , O'Grady, J. , Kersten, Mclean Phillip M., Angstman, Kurt B. , O'Grady, Jason S, O'Grady, Jason S

Mayo Clinic

Family Medicine | May 21, 2019 | Volume: 51 | Issue: 7 | Pages: 574-577

10.22454/fammed.2019.659478 | PMID 31125421 Get It

Background and Objectives: Demographic trends show an increasing older adult population. Therefore, family medicine training programs may need to reevaluate how well their residents perform clinic procedures essential to older adults. Our objective was to compare the rates of the most frequently performed clinic procedures for Medicare patients in a large multiregional health care system (MRHCS) with those in a family medicine residency clinic. Methods: In this retrospective cohort study, Current Procedural Terminology coding data were queried from the billing systems of an MRHCS (the control group) and a family medicine residency clinic (the study group) for a 3-year period. The primary outcome was the procedural rate ratios per 1,000 office visits for the 10 most common clinic procedures in the MRHCS billed to Medicare. Results: The study group consisted of 19,099 office visits by Medicare patients to the residency clinic; the control group consisted of 2,034,188 visits to the MRHCS. Except for large joint injection, procedural rates were significantly different for the other nine procedures (destruction of benign skin lesions, nail care, punch or shave skin biopsy, removal of impacted cerumen, wound debridement of skin, Unna boot application, excision of skin lesion, paring of corn or callus, and insertion of bladder catheter). The rate of skin excision was higher in the residency clinic than in the MRHCS but lower for the other eight procedures. Conclusions: These data suggest that teaching programs may need to adapt to meet the current and future practice needs of this increasing patient population.
Abstract LB-242: Aberrant crypt foci (ACF) are not surrogate biomarkers of sporadic adenoma prevention with celecoxib: Results from the Adenoma Prevention with Celecoxib (APC) trial
Cho, Nancy L. , Redston, Mark , Carothers, Adelaide M., Wilton, Andrew S. , Sontag, Stephen J. , Nishioka, Norman S., Giardiello, Frances, Saltzman, John R. , Gostout, Chris, Eagle, Craig, Hawk, Ernest T. , Zauber, Ann Graham , Hornick, Jason L. , Bertagnolli, Monica M.

Mayo Clinic

Cancer Research | May 11, 2019 | Volume: 68 | Issue: 9_Supplement | Pages: LB-242-LB-242

10.1158/1538-7445.am2008-lb-242 Get It

Abstract Aberrant crypt foci (ACF) are the earliest visible neoplastic lesions in the colorectum. The natural history of these lesions and their role in the adenoma-carcinoma sequence are unknown. We studied ACF in a subset of patients enrolled in the Adenoma Prevention with Celecoxib (APC) Trial to determine whether the presence of ACF in the rectum correlated with that of adenomas in the entire large intestine. Participants were randomized to placebo (n=17), celecoxib 200 mg bid (n=15), or celecoxib 400 mg bid (n=13). Magnification chromoendoscopy (MCE) was performed to identify and biopsy ACF within the rectum at baseline and after 8-12 months of medication use. A total of 670 ACF were identified in 45 patients, and 70 of these were examined histologically. All of the ACF examined were non-dysplastic. Analysis showed no differences in ACF number between baseline and post-treatment studies (8.3±1.0 vs. 6.3±1.1) and no modulation by treatment (celecoxib vs placebo; p=0.77). Immunohistochemical studies showed that ACF contained cells exhibiting increased proliferation, but lacked other features of neoplasia such as increased Cox-2 expression and microvascular density, nuclear localization of β-catenin, or decreased expression of the tumor suppressors SMAD4, estrogen receptor (ERα) or MGMT. Of the secondary markers assessed at baseline, only SMAD4 expression correlated with post-treatment adenoma recurrence. Taken together, these data showed that non-dysplastic ACF are not accurate surrogate endpoint biomarkers of colorectal adenoma risk or NSAID chemoprevention response.
SUN-092 Distinct Changes in Gut Microbiota Are Associated with Estradiol-Mediated Protection from Diet-Induced Obesity in Female Mice
Graham, Madeline , Noh, Hye Lim, Suk, Sujin, Friedline, Randall H. , Kim, Jason , Acharya, Kalpana D. , Chen, Jun , Tetel, Marc J.

Mayo Clinic

Journal of the Endocrine Society | May 10, 2019 | Volume: 3 | Issue: Supplement_1 | Pages: No page available

10.1210/js.2019-sun-092 Get It

Abstract C61: High fat triggers oncogenic K-Ras activity and a COX2 dependent feed-forward loop to induce pancreatic ductal adenocarcinoma development
Philip, Bincy, Daniluk, Jarek, Liu, Yan , Gomez, Sobeyda, Ji, Baoan , Haojie, Huang, Fleming, Jason B. , Logsdon, Craig D. , Cruz‐Monserrate, Zobeida , Roland, Christina Lynn , Chatterjee, Deyali , Haojie, Huang, Wang, Huamin

Mayo Clinic

Cancer Prevention Research | May 9, 2019 | Volume: 6 | Issue: 11_Supplement | Pages: C61-C61

10.1158/1940-6215.prev-13-c61 Get It

Abstract Obesity is a risk factor for Pancreatic Ductal Adenocarcinoma (PDAC), but the molecular mechanisms involved are unclear. Oncogenic mutation of K-Ras occurs early and nearly universally in patients with this disease. However, recent evidence indicates that oncogenic Ras is not fully active and for activity to surpass the threshold required to engage a Ras-inflammation feed-forward loop, it requires a stimulus. We hypothesized that high-fat intake acts as an inflammatory stimulus, increasing K-Ras activity and that cyclooxygenase -2 (COX2) expression is required in the inflammatory loop. LSL-K-Ras mice were crossed with elastase-CreER (acinar cell-specific) or Pdx1-Cre (pancreatic cell-specific) to “knock-in” expression of oncogenic K-Ras. Additionally, acinar cell-specific -Ras mice were crossed with COX2 conditional knockout mice. All mice were fed isocaloric diets with different amounts of fat and a COX2 inhibitor was administered to some acinar cell-specific -Ras mice. Pancreata were analyzed for Ras activity, Phospho-ERK levels, inflammation, fibrosis, PanIN and PDAC development. We observed that consumption of a high fat diet (HFD) led to increased K-Ras activity, PanIN formation, fibrotic stroma and PDAC development compared to a control diet. Additionally, we observed a significant reduction in the survival of mice fed a HFD. Genetic deletion of COX2 in acinar cells and COX2 systemic inhibition prevented the HFD-induced effects in acinar cell-specific -Ras mice. These findings indicated that a HFD stimulates activation of oncogenic K-Ras and initiates an inflammatory feed-forward loop requiring the expression of COX2 leading to pancreatic inflammation, fibrosis, PanINs and PDAC. This mechanism may explain the PDAC risks associated with consumption of a HFD. Citation Format: Bincy Philip, Christina L. Roland, Jarek Daniluk, Yan Liu, Deyali Chatterjee, Sobeyda Berenice Gomez, Baoan Ji, Huang Haojie, Huamin Wang, Jason B. Fleming, Craig D. Logsdon, Zobeida Cruz-Monserrate. High fat triggers oncogenic K-Ras activity and a COX2 dependent feed-forward loop to induce pancreatic ductal adenocarcinoma development. [abstract]. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27-30; National Harbor, MD. Philadelphia (PA): AACR; Can Prev Res 2013;6(11 Suppl): Abstract nr C61.
Diffuse Midline Glioma H3 K27M-Mutant Manifested as Progressive Paraplegia
Goldstein, Eric , Kyper, Christopher M., Siegel, Jason , Goldstein, Eric D , Siegel, Jason L, Kyper, Christopher

Mayo Clinic

The Neurohospitalist | May 8, 2019 | Volume: 10 | Issue: 1 | Pages: 73-74

10.1177/1941874419847347 | PMID 31839872 Get It

Volumetric laser endomicroscopy and its application to Barrett's esophagus: results from a 1,000 patient registry
Smith, Michael S. , Konda, Vani J. , Gordon, Stuart R. , DeMeester, Steven R. , Joshi, Vivek , Ganguly, Eric K. , Mashimo, Hiroshi , Jobe, Blair A. , McKinley, Matthew , Wallace, Michael B. , Thakkar, Shyam , Schnoll‐Sussman, Felice , Sharaiha, Reem Z. , Tarnasky, P, Wolfsen, Herbert C. , Hawes, Robert H. , Lipham, John C. , Khara, Harshit S. , Navaneethan, U, Kedia, Prashant , Hasan, Muhammad K. , Sethi, Amrita , Samarasena, Jason , Siddiqui, Uzma D. , Gress, Frank G., Rodríguez, Reynaldo , Lee, C, Gonda, Tamas A. , Waxman, Irving , Hyder, S., Poneros, John M., Sharzehi, Kaveh , Palma, Jack A. Di, Sejpal, Divyesh V., Hagen, J. A., Rothstein, Richard, Sawhney, Mandeep , Malik, Zubair , Chang, Kenneth J. , Fichera, Alessandro , Gaidhane, Monica , Wallace, Michael B , Cash, Brooks D. , Trindade, Arvind J. , Diehl, David L. , Singh, Satish K. , Komatsu, Y, Kahaleh, Michel , Pleskow, Douglas K. , Hyder, S, Oh, Daniel S. , Berzin, Tyler M.

Mayo Clinic

Diseases of the Esophagus | April 30, 2019 | Volume: 32 | Issue: 9 | Pages: No page available

10.1093/dote/doz029 | PMID 31037293 Get It

SUMMARY Volumetric laser endomicroscopy (VLE) uses optical coherence tomography (OCT) for real-time, microscopic cross-sectional imaging. A US-based multi-center registry was constructed to prospectively collect data on patients undergoing upper endoscopy during which a VLE scan was performed. The objective of this registry was to determine usage patterns of VLE in clinical practice and to estimate quantitative and qualitative performance metrics as they are applied to Barrett's esophagus (BE) management. All procedures utilized the NvisionVLE Imaging System (NinePoint Medical, Bedford, MA) which was used by investigators to identify the tissue types present, along with focal areas of concern. Following the VLE procedure, investigators were asked to answer six key questions regarding how VLE impacted each case. Statistical analyses including neoplasia diagnostic yield improvement using VLE was performed. One thousand patients were enrolled across 18 US trial sites from August 2014 through April 2016. In patients with previously diagnosed or suspected BE (894/1000), investigators used VLE and identified areas of concern not seen on white light endoscopy (WLE) in 59% of the procedures. VLE imaging also guided tissue acquisition and treatment in 71% and 54% of procedures, respectively. VLE as an adjunct modality improved the neoplasia diagnostic yield by 55% beyond the standard of care practice. In patients with no prior history of therapy, and without visual findings from other technologies, VLE-guided tissue acquisition increased neoplasia detection over random biopsies by 700%. Registry investigators reported that VLE improved the BE management process when used as an adjunct tissue acquisition and treatment guidance tool. The ability of VLE to image large segments of the esophagus with microscopic cross-sectional detail may provide additional benefits including higher yield biopsies and more efficient tissue acquisition. Clinicaltrials.gov NCT02215291